Diamir

Founded in Monmouth Junction, United States, DiamiR is a pioneering molecular diagnostics company dedicated to developing minimally invasive solutions for the early detection and monitoring of brain and synaptic health conditions, such as mild cognitive impairment and Alzheimer’s disease. The company's core mission is to enable earlier intervention and better care planning through their innovative technology, which utilizes brain-enriched microRNA biomarkers in plasma. DiamiR collaborates with academia, medical centers, disease foundations, and industry partners to advance their diagnostic solutions.

DiamiR has garnered attention through its peer-reviewed publications, grant awards, and patents, establishing itself as a notable player in the field of neurodiagnostics. The company’s leadership includes experts in molecular biology and diagnostics, and it has attracted investment from both private and institutional investors. DiamiR's impact is significant in the realm of brain health, offering promising advancements in the early detection and monitoring of neurodegenerative and neurodevelopmental disorders, thereby contributing to healthier aging and improved patient outcomes.